Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Other(1)

Detailed Status

Recruiting2
unknown1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

unknown120%
active_not_recruiting120%
not_yet_recruiting120%
recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_1

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

NCT05277168
active_not_recruitingphase_1

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

NCT04877717
not_yet_recruitingphase_2

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

NCT06881017
recruitingphase_3

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06649292
unknownphase_1

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

NCT04928625

Clinical Trials (5)

Showing 5 of 5 trials
NCT05277168Phase 1

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Recruiting
NCT04877717Phase 1

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Active Not Recruiting
NCT06881017Phase 2

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not Yet Recruiting
NCT06649292Phase 3

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT04928625Phase 1

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5